Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging

Cho, Young-Seok; Yoon, Tae‐Jong; Jang, Eue‐Soon; Hong, Kwan Soo; Lee, Shin Young; Kim, Ok Ran; Park, Cheong-Soo; Kim, Yong-Jin; Yi, Gyu‐Chul; Chang, Kiyuk

doi:10.1016/j.canlet.2010.08.004

Cited by 93 publications

(49 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study reporting the use of MNPs as tools for magnetofection [51] and consequently for the enhancement of siRNA delivery using external magnetic fields have also been widely described [23,[52][53][54][55]. Superparamagnetic iron oxide nanoparticles (SPIONs) are another example of siRNA-magnetic carriers, which are also widely studied MR contrast agents useful in both imaging and drug delivery applications [56][57][58].…”

Section: Magnetic Nanoparticles For Rnaimentioning

confidence: 99%

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

et al. 2015

View full text Add to dashboard Cite

RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells; opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the "do's and dont's" of the 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 REVIEW NANO TODAY 2 inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15. *Manuscript Click here to view linked References

show abstract

Section: Magnetic Nanoparticles For Rnaimentioning

confidence: 99%

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Same antibody has been studied as versatile SPECT and PET imaging agent in several cancer models, e.g. malignant mesothelioma, prostate cancer, head-and-neck squamous cell carcinoma, ovarian carcinoma (Figure 2.), colon cancer and universally EGFR positive tumors (Nayak et al 2011, Malmberg et al 2011, Hoeben et al 2011, Huhtala et al 2010, Cho et al 2010, Ping Li et al 2008.…”

Section: Proteinsmentioning

confidence: 99%

Small Animal Imaging in Development of New Generation Diagnostic and Therapeutic Agents

Huhtala¹,

Närvänen²

2012

Pharmacotherapy

View full text Add to dashboard Cite

“…(Table 1) Table 1. Gene therapy formulations with eluting drugs -Magneto-fluorescent silica nanoparticles (MFSN) [70] -Folic acid conjugated guar gum nanoparticles (MTXFA-GGNP) -Wheat germ agglutinin (WGA)-functionalised chitosan-Ca-alginate (CTS-Ca-ALG) microparticles (MPs) [71] -Anti-VEGF antibodyconjugated dextran-coated iron oxide nanoparticles (anti-EGF-NPs) [72] -HA modified mesoporous silica nanoparticles (HA-MSNs) [73] Discussion Current screening methodology is efficient, however; a novel approach regarding therapy is needed. Several efforts have been made towards identifying the genome of CRC cancer and therefore providing targeted therapy, mostly in the form of chemotherapy or inhibitors.…”

Section: Gene Therapymentioning

confidence: 99%

Colorectal Cancer from Molecular Pathways to Gene Therapy

Kosmıdis¹,

Efthimidis²,

Baka³

et al. 2017

Oncomedicine

View full text Add to dashboard Cite

Nowadays colorectal cancer is still considered the third most common cancer in the world. The tumorigenesis mechanisms of colorectal cancer have been widely studied at a molecular level. It has been observed that morbidity and mortality caused by colorectal cancer impacts on the global economy. This occurs through the loss of productivity and the burden on the healthcare system. Therefore an effort is made by several researchers to expend considerably their resources to develop treatments and preventative strategies to reduce the incidence of colorectal cancer. A Large-scale sequencing of genome, proteome, microbiome, and transcriptome analyses of colorectal cancer tissue has allowed researchers to better understand colorectal cancer subtypes. Until now the following parameters have been identified with the etiology of colorectal cancer genetic mutations, inflammatory processes, diet, and the gut microbes. In the current review we will present the molecular pathways of CRC and discuss novel gene therapy approaches.

show abstract

Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging

Cited by 93 publications

References 30 publications

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

Small Animal Imaging in Development of New Generation Diagnostic and Therapeutic Agents

Colorectal Cancer from Molecular Pathways to Gene Therapy

Contact Info

Product

Resources

About